UNIVERSAL CANCER TECHNOLOGIES

UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in the subject's sample from a routine blood draw. The test can detect the majority of cancer types at all stages (stage I through IV), even before a subject may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT's CA-62 biomarker test can also be used to monitor the success of ongoing cancer treatments as well as identify relapses in remission patients... UCT is managed by a team of dedicated international scientists and professionals, focused on the single goal of saving lives by accelerating the detection of cancer.

Also known as: UCT

Primary location: Toronto Canada